Table 2.

Outcomes

Signed Consent (N)	28
Registered	26
Screen Failures (N)	6
Tissue not available	5
Tissue not usable	1
Time from consent to tissue availability, days (range)
All	2.5 (0–21)
New specimen (N=12)	0 (0–13)
Archival (N=8)	4.5 (1–21)
Time from biopsy to specimen shipment, days (range) (N=12)	4 (2–7)
Time from specimen shipment to report from FM, days (range)	15.5 (12–30)
Time from report to tumor board, days (range)	5 (3–10)
Recommendation within 28 days of biopsy
Yes	12 (60%)
No	8 (40%)
Successful NGS of metastatic biopsy (N)	20
Potentially actionable mutation identified (N)	15
Tumor board recommended targeted therapy as possible next treatment (N)	13
Received targeted therapy as next treatment (4)*	4

^*A patient with an AR+ tumor received bicalutamide on study, a patient with a BAP1 mutation received carboplatin/PARP inhibitor on study, a patient with a MAP2K1 amplification received trametinib off study, and a patient with an ERBB2 mutation received trastuzumab off study.